A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

Sponsor
University Health Network, Toronto
Study ID
NCT02428270
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GSK2256098 — DRUG
    Small molecule inhibitor of focal adhesion kinase (FAK)
  • Trametinib — DRUG
    Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.

Study Details

This is a phase 2 study (the second phase in testing a new drug or combination to see how effect the drug or combination is) of investigational drugs GSK2256098 and Trametinib. The purpose of the study is to evaluate the antitumor activity of GSK2256098 and Trametinib in patients with advanced pancreatic cancer.

Key Dates

Start date
Apr 30, 2016
Status verified
Oct 2022
Primary completion
Jun 30, 2017
Completion
Oct 27, 2022

Study Design

Enrollment
16 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GSK2256098 and Trametinib
    GSK2256098, orally, at 0.375 or 0.5 mg, once daily, continuously every 28 day cycles. Trametinib, orally at 250 mg or 500 mg, twice daily, continuously every 28 day cycles.

Primary Outcome Measure

Percentage of patients who experience complete response, partial response, or stable disease [ Time Frame: 24 weeks ]

Related Studies